Considerations regarding adherence of anti-osteoporosis therapy

Violet Lagari-Libhaber, Elizabeth McAninch, Sanford Baim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Osteoporosis remains a challenging disease to treat due to a number of barriers including patient adherence to therapies. One of the most recent advances has been the development of the Fracture Risk Assessment Tool, which is helpful in conveying fracture risk to patients and providing treatment guidance to clinicians. The decision to use an anti-osteoporosis therapy must be tailored to the patient's specific clinical scenario. The bisphosphonates are first-line agents in the treatment of osteoporosis and are efficacious in substantially reducing fracture risk between 25% and 70% on average depending on fracture site. Compliance with oral bisphosphonate pills can be poor, resulting in a significant deterrent to the proper management of osteoporosis. Non-pill forms of bisphosphonate and nonbisphosphonate therapy are available for the treatment of osteoporosis and may increase compliance. Among these is Binosto, a new formulation of weekly effervescent alendronate, as well as intravenous bisphosphonates, teriparatide, and subcutaneously administered denosumab, which are all costly medications and are unlikely to become the mainstay of treatment over the oral bisphosphonate pills. Having a detailed conversation between the patient and physician is essential to the development of a tailored treatment plan that will decrease fracture risk.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalPostgraduate Medicine
Volume127
Issue number1
StatePublished - Jan 1 2015

Fingerprint

Osteoporosis
Diphosphonates
Therapeutics
Teriparatide
Alendronate
Patient Compliance
Compliance
Physicians

Keywords

  • adherence
  • bisphosphonates
  • osteoporosis
  • treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Considerations regarding adherence of anti-osteoporosis therapy. / Lagari-Libhaber, Violet; McAninch, Elizabeth; Baim, Sanford.

In: Postgraduate Medicine, Vol. 127, No. 1, 01.01.2015, p. 92-98.

Research output: Contribution to journalArticle

Lagari-Libhaber, Violet ; McAninch, Elizabeth ; Baim, Sanford. / Considerations regarding adherence of anti-osteoporosis therapy. In: Postgraduate Medicine. 2015 ; Vol. 127, No. 1. pp. 92-98.
@article{4750b1d6bca74e5f928f9e61417a841c,
title = "Considerations regarding adherence of anti-osteoporosis therapy",
abstract = "Osteoporosis remains a challenging disease to treat due to a number of barriers including patient adherence to therapies. One of the most recent advances has been the development of the Fracture Risk Assessment Tool, which is helpful in conveying fracture risk to patients and providing treatment guidance to clinicians. The decision to use an anti-osteoporosis therapy must be tailored to the patient's specific clinical scenario. The bisphosphonates are first-line agents in the treatment of osteoporosis and are efficacious in substantially reducing fracture risk between 25{\%} and 70{\%} on average depending on fracture site. Compliance with oral bisphosphonate pills can be poor, resulting in a significant deterrent to the proper management of osteoporosis. Non-pill forms of bisphosphonate and nonbisphosphonate therapy are available for the treatment of osteoporosis and may increase compliance. Among these is Binosto, a new formulation of weekly effervescent alendronate, as well as intravenous bisphosphonates, teriparatide, and subcutaneously administered denosumab, which are all costly medications and are unlikely to become the mainstay of treatment over the oral bisphosphonate pills. Having a detailed conversation between the patient and physician is essential to the development of a tailored treatment plan that will decrease fracture risk.",
keywords = "adherence, bisphosphonates, osteoporosis, treatment",
author = "Violet Lagari-Libhaber and Elizabeth McAninch and Sanford Baim",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "127",
pages = "92--98",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - Considerations regarding adherence of anti-osteoporosis therapy

AU - Lagari-Libhaber, Violet

AU - McAninch, Elizabeth

AU - Baim, Sanford

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Osteoporosis remains a challenging disease to treat due to a number of barriers including patient adherence to therapies. One of the most recent advances has been the development of the Fracture Risk Assessment Tool, which is helpful in conveying fracture risk to patients and providing treatment guidance to clinicians. The decision to use an anti-osteoporosis therapy must be tailored to the patient's specific clinical scenario. The bisphosphonates are first-line agents in the treatment of osteoporosis and are efficacious in substantially reducing fracture risk between 25% and 70% on average depending on fracture site. Compliance with oral bisphosphonate pills can be poor, resulting in a significant deterrent to the proper management of osteoporosis. Non-pill forms of bisphosphonate and nonbisphosphonate therapy are available for the treatment of osteoporosis and may increase compliance. Among these is Binosto, a new formulation of weekly effervescent alendronate, as well as intravenous bisphosphonates, teriparatide, and subcutaneously administered denosumab, which are all costly medications and are unlikely to become the mainstay of treatment over the oral bisphosphonate pills. Having a detailed conversation between the patient and physician is essential to the development of a tailored treatment plan that will decrease fracture risk.

AB - Osteoporosis remains a challenging disease to treat due to a number of barriers including patient adherence to therapies. One of the most recent advances has been the development of the Fracture Risk Assessment Tool, which is helpful in conveying fracture risk to patients and providing treatment guidance to clinicians. The decision to use an anti-osteoporosis therapy must be tailored to the patient's specific clinical scenario. The bisphosphonates are first-line agents in the treatment of osteoporosis and are efficacious in substantially reducing fracture risk between 25% and 70% on average depending on fracture site. Compliance with oral bisphosphonate pills can be poor, resulting in a significant deterrent to the proper management of osteoporosis. Non-pill forms of bisphosphonate and nonbisphosphonate therapy are available for the treatment of osteoporosis and may increase compliance. Among these is Binosto, a new formulation of weekly effervescent alendronate, as well as intravenous bisphosphonates, teriparatide, and subcutaneously administered denosumab, which are all costly medications and are unlikely to become the mainstay of treatment over the oral bisphosphonate pills. Having a detailed conversation between the patient and physician is essential to the development of a tailored treatment plan that will decrease fracture risk.

KW - adherence

KW - bisphosphonates

KW - osteoporosis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84941561664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941561664&partnerID=8YFLogxK

M3 - Article

C2 - 25526234

AN - SCOPUS:84941561664

VL - 127

SP - 92

EP - 98

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -